We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




System Offers Both Morphology Preservation and Biomolecule Stabilization

By LabMedica International staff writers
Posted on 02 Feb 2009
An integrated laboratory system for sample fixation, stabilization, and purification is available. More...
The system allows scientists to perform histology, immunohistochemistry, and stabilized nucleic acid extractions from one sample without compromising workflow.

The system has two components: a tissue container and tissue kits. The dual-chambered container is prefilled with two reagents: a tissue fixative for fast penetration and fixation, and a tissue stabilizer for storage and transport. The fixation process uses a standard histocasette with a fixative that is an alternative to formalin and is stopped when the sample is transferred into the stabilizer. Fixation time is standardized at two to four hours.

The sample remains stable in the tissue stabilizer for transport and storage prior to processing. The tissue can then be paraffin embedded and processed in pathology workflows. After the tissue sample has been stabilized in tissue containers (and optionally paraffin embedded), ribonucleic acid (RNA), micro (mi)RNA, and DNA can be purified using tissue kits.

Laboratories working with human and animal tissue need to conduct a variety of analyses on limited sample materials. The recognized standard for preserving tissue morphology is formalin fixation/paraffin embedding (FFPE). This method provides excellent results for morphological studies, but it does not preserve biomolecules. As a result, the DNA, RNA, and miRNA molecules degrade, preventing the complete analysis required. This would hinder applications such as the development of diagnostics and therapeutics, biomarker discovery, and case-controlled and population-based clinical studies.

The technology, called the PAXgene tissue system, is the newest addition to Qiagen's (Frankfurt, Germany) suite of tissue management technologies. The suite includes integrated products that standardize all steps of the workflow, starting with archived or prospectively collected tissues and ending with data analysis. This ensures comparability and reproducibility of data from laboratory to laboratory.

Qiagen is a global provider of sample and assay technologies. Sample technologies are used to isolate and process nucleic acids and proteins from biologic samples such as blood or tissue. Assay technologies are used to make such isolated biomolecules visible. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutic, and biotechnology companies.

Related Links:

Qiagen




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
Platelet Function Analyzer
PL-12
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.